DLQ-01 (latanoprost)
Phase 1/2TopicalProstaglandin
No public activity in over 18 months
- Developed by
- DermaLiq Therapeutics
- Current phase
- Phase 1/2
- Indications
- Androgenetic alopecia
- Also known as
- DLQ01, latanoprost topical
- Last public activity
- April 2024
- Record confidence
- Medium
A combined safety and early-efficacy study.
Development history
- Phase 1/2
First Phase 1/2 trial on record: NCT05636904 — Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
Dermaliq Therapeutics, Inc. · n=120 · December 2022
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Safety and Efficacy Study of Topical DLQ01 in Androgenetic Alopecia — ClinicalTrials.gov
- Dermaliq announces positive topline results from the Phase 1b/2a trial of DLQ01 in androgenetic alopecia in men — Company release, July 2024